About Tryptophan 2,3-dioxygenase
Tryptophan 2,3-dioxygenase (TDO2) is a protein
from Homo sapiens identified by UniProt accession
P48775, 406 residues long.
MolForge cross-references it against 0 known binders and
258 disease associations.
Target properties
| Protein name | Tryptophan 2,3-dioxygenase |
|---|
| UniProt accession | P48775 |
|---|
| Gene | TDO2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 406 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (258)
Diseases linked to this target (Open Targets).
- familial hypertryptophanemia · score 0.51
- Hypertryptophanemia · score 0.46
- blood metabolite measurement · score 0.31
- hepatocellular carcinoma · score 0.12
- hypospadias · score 0.11
- neoplasm · score 0.10
- breast cancer · score 0.09
- speech perception · score 0.08
- esophageal squamous cell carcinoma · score 0.08
- systolic blood pressure · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P48775-F1 | alphafold | PREDICTED | 90.06 | — |
Amino-acid sequence (406 residues)
MSGCPFLGNN FGYTFKKLPV EGSEEDKSQT GVNRASKGGL IYGNYLHLEK VLNAQELQSE TKGNKIHDEH LFIITHQAYE LWFKQILWEL DSVREIFQNG HVRDERNMLK VVSRMHRVSV ILKLLVQQFS ILETMTALDF NDFREYLSPA SGFQSLQFRL LENKIGVLQN MRVPYNRRHY RDNFKGEENE LLLKSEQEKT LLELVEAWLE RTPGLEPHGF NFWGKLEKNI TRGLEEEFIR IQAKEESEEK EEQVAEFQKQ KEVLLSLFDE KRHEHLLSKG ERRLSYRALQ GALMIYFYRE EPRFQVPFQL LTSLMDIDSL MTKWRYNHVC MVHRMLGSKA GTGGSSGYHY LRSTVSDRYK VFVDLFNLST YLIPRHWIPK MNPTIHKFLY TAEYCDSSYF SSDESD
Explore Tryptophan 2,3-dioxygenase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets